Assuntos
Ansiolíticos/uso terapêutico , Ansiedade/tratamento farmacológico , Benzodiazepinas/uso terapêutico , Adolescente , Adulto , Benzodiazepinas/efeitos adversos , Ensaios Clínicos como Assunto , Eletroencefalografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Placebos , Escalas de Graduação PsiquiátricaRESUMO
Both oral and intravenous TRH produce systematic alterations in brain function of depressive patients as determined by scalp-recorded computerized cerebral biopotentials (computer EEG). The computer EEG (CEEG) profiles of both formulations are not only very similar to each other, but also resemble the CEEG profiles of psychostimulant compounds (Bio-availability). As in CEEG findings, TSH plasma levels also indicate that oral TRH is indeed an active compound. Although some "antidepressive" effects were observed after both formulations, they were not present in every patient, and it was not always the case after repetitive TRH administration, nor were the effects on depressed mood too impressive. On the other hand, in almost all patients certain behavioral effects of TRH were seen which related to "life instincts" and "life performance". The increase of interest, desire and drive for work, food and sex was one of the most striking findings, particularly after intravenous TRH. This may be responsible for the "antidepressive" effects of TRH in patients in whom depression may be the result of an inhibition of "instinctive" functions.
Assuntos
Depressão/tratamento farmacológico , Hormônio Liberador de Tireotropina/administração & dosagem , Administração Oral , Adulto , Idoso , Transtorno Bipolar/tratamento farmacológico , Ensaios Clínicos como Assunto , Avaliação de Medicamentos , Eletroencefalografia , Feminino , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Tireotropina/sangue , Hormônio Liberador de Tireotropina/efeitos adversos , Hormônio Liberador de Tireotropina/uso terapêutico , Gravação de VideoteipeAssuntos
Hormônio Liberador de Tireotropina/farmacologia , Administração Oral , Comportamento/efeitos dos fármacos , Depressão/tratamento farmacológico , Humanos , Infusões Parenterais , Escalas de Graduação Psiquiátrica , Hormônio Liberador de Tireotropina/administração & dosagem , Hormônio Liberador de Tireotropina/uso terapêuticoRESUMO
Based on qualitative and quantitative EEG findings, the psychotropic properties of GB-94, GC-46, and GC-94 were predicted. According to the EEG model, GB-94 was predicted to be similar to amitriptyline and GC-46 t( imipramine. GC-94 was found to be much less effective on the CNS than GB-94 and GC-46 and was predicted to have "stimulatory" clinical effects similar to desipramine. The clinical trials demonstrated that GB-94 is indeed an antidepressive psychotropic compound similar to amitriptyline. GB-94 in lower dosages was also found to be effective in anxiety syndromes. In some schizophrenics GB-94 showed some therapeutic effects, while in others it obviously exacerbrated the psychotic symptomatology. GC-94 was not found to be significantly effective in a heterogenous psychiatric population. Only slight improvement in some schizophrenic patients was observed However, a noticeable worsening in the symptomatology of manic and hypomanic patients was seen. The study demonstarted that GC-94 indeed has a central stimulatory effect, but no minor or major tranquilizer properties or sedative antidepressive qualities were observed. GC-46 was tried in only three subjects. Based on this pilot trial, no conclusion can be made about the psychotropic properties of this compound. Our quantitative pharmaco-EEG and clinical trials clearly demonstrated the significant value of quantitative EEG in early screening of psychoactive drugs in order to predict their clinical values and effective dosage ranges.
